Malignant tumors of the nose and paranasal sinuses: a retrospective review of a Portuguese cancer center’s experience
- Authors: Castelhano L.G.1, Correia F.A.1, Raposo D.F.2, Campos A.H.3, Melo M.R.2, Pereira S.A.4, Mariano M.C.4, Ferreira L.5, Montalvão P.5, Magalhães M.T.5
-
Affiliations:
- Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental R
- Hospital Prof. Doutor Fernando Fonseca
- Hospital CUF Tejo
- Hospital de São José, Centro Hospitalar Universitário de Lisboa Central
- Instituto Português de Oncologia Francisco Gentil
- Issue: Vol 11, No 3 (2021)
- Pages: 10-17
- Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
- Published: 10.11.2021
- URL: https://ogsh.abvpress.ru/jour/article/view/669
- DOI: https://doi.org/10.17650/2222-1468-2021-11-3-10-17
- ID: 669
Cite item
Full Text
Abstract
Introduction. Although uncommon from a population-based perspective, there is considerable morbidity and mortality associated with malignant tumors of the nose and paranasal sinuses.
The objective of this study was to characterize the presentation, risk factors, management and survival of patients with these tumors treated at a single institution.
Materials and methods. We retrospectively reviewed the clinical records of patients with malignancies of the nose and paranasal sinuses diagnosed between January 2010 and December 2014 at a tertiary cancer center. Univariate and multivariate analysis were performed.
Results. Ninety patients were included in the study. Mean age at diagnosis was 62.8 years (range, 2–95 years) and mean follow-up was 44.5 months (range, 2–113 months). The maxillary sinus (33.3 %) and the nasal cavity (32.2 %) were the most frequent sites of origin. Squamous cell carcinoma (36.7 %), mucosal melanoma (15.6 %) and adenoid cystic carcinoma (10 %) were the most common histologic subtypes. Surgery was the primary treatment for 86.7 % of patients. Recurrence occurred in 45 patients (50 %). The overall 5‑year survival was 39.3 % and disease free-survival was 45.9 %. Survival was significantly decreased in non-smokers (p = 0.022), T3–4 tumors (p = 0.007), positive lymph nodes (p <0.001), nonepithelial tumors (p = 0.036) and positive margins (p = 0.032). Survival was not affected by surgical approach between endoscopic, open and combined approaches (p = 0.088).
Conclusion. Prognosis is poor, with high recurrences and low survival, but clearly histology, location and stage-dependent. Sound oncologic principles, with complete resections and negative margins, result in a better outcome.
About the authors
L. G. Castelhano
Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental R
Author for correspondence.
Email: lmgcastelhano@gmail.com
ORCID iD: 0000-0001-6501-6941
Department of Otolaryngology
126 R. da Junqueira, Lisboa 1349–019
PortugalF. A. Correia
Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental R
Email: fake@neicon.ru
Department of Otolaryngology
126 R. da Junqueira, Lisboa 1349–019
PortugalD. F. Raposo
Hospital Prof. Doutor Fernando Fonseca
Email: fake@neicon.ru
ORCID iD: 0000-0001-9337-0737
Department of Otolaryngology
IC19, Amadora 2720–276, Portugal
PortugalA. H. Campos
Hospital CUF Tejo
Email: fake@neicon.ru
Department of Otolaryngology
Av. 24 de Julho 171A, 1350–352 Lisboa
PortugalM. R. Melo
Hospital Prof. Doutor Fernando Fonseca
Email: fake@neicon.ru
Department of Otolaryngology
IC19, Amadora 2720–276
PortugalS. A. Pereira
Hospital de São José, Centro Hospitalar Universitário de Lisboa Central
Email: fake@neicon.ru
ORCID iD: 0000-0002-8341-078X
Department of Otolaryngology
R. José António Serrano, Lisboa 1150–199
PortugalM. C. Mariano
Hospital de São José, Centro Hospitalar Universitário de Lisboa Central
Email: fake@neicon.ru
ORCID iD: 0000-0002-6898-9631
Department of Otolaryngology
R. José António Serrano, Lisboa 1150–199
PortugalL. Ferreira
Instituto Português de Oncologia Francisco Gentil
Email: fake@neicon.ru
ORCID iD: 0000-0001-7268-7495
Department of Otolaryngology
R. Prof. Lima Basto, Lisboa 1099–023
PortugalP. Montalvão
Instituto Português de Oncologia Francisco Gentil
Email: fake@neicon.ru
Department of Otolaryngology
R. Prof. Lima Basto, Lisboa 1099–023
PortugalM. T. Magalhães
Instituto Português de Oncologia Francisco Gentil
Email: fake@neicon.ru
Department of Otolaryngology
R. Prof. Lima Basto, Lisboa 1099–023
PortugalReferences
Supplementary files


